Publications by authors named "Sudheshna Vemula"
Purpose: Glioblastoma (GBM) is the most common primary brain cancer in adults with a very poor prognosis. Metabolic drivers of tumorigenesis are highly relevant within the central nervous system, where glucose is the critical source of energy. The impact of obesity on survival outcomes in patients with GBM is not well established.
View Article and Find Full Text PDFArticle Synopsis
- Radiation treatment has become the preferred option for uveal melanoma, moving away from the more invasive enucleation approach; a new frameless LINAC solution for fractionated stereotactic radiosurgery (fSRS) was developed to preserve the eye.
- A unique ocular localization box was created featuring adjustable LED lights for patient focus, eye position monitoring with a CCD camera, and tools to track eye movement, ensuring targeted and effective treatment sessions.
- Initial trials with 10 patients showed that the localization box was effective and well-tolerated, yielding high accuracy for positioning with minimal setup errors, paving the way for future trials to further assess its effectiveness and consistency in various settings.*
Background: To assess the anatomical and functional outcomes in eyes with persistent diabetic macular oedema (pDME) on chronic anti-vascular endothelial growth factor therapy switched to intravitreal faricimab.
Methods: Patients with pDME on chronic anti-vascular endothelial growth factor therapy that were switched to faricimab and received at least three injections at our institution between April 2022 and May 2023 were included in this study. Patients were excluded if they had complete response to previous treatment but were switched to extend treatment intervals if they had steroid or laser treatment for DME within 6 months prior to switch.
Purpose: To assess the anatomic and functional outcomes in eyes with neovascular age-related macular degeneration (nAMD) previously treated with anti-VEGF therapy in response to intravitreal faricimab.
Design: Retrospective, interventional, consecutive case series.
Subjects: Patients with previously treated nAMD who received ≥ 4 consecutive injections of faricimab were included.